2010's Top Biopharma Dealmakers
Executive SummaryGenerics, emerging markets, orphan diseases and earn-out heavy M&A were the recurring dealmaking themes in 2010. We focus here on the dealmakers, showing which companies dominated the dealmaking landscape in terms of deal volume and value, as well as the therapeutic categories that grabbed the most attention.
You may also be interested in...
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.